CDRH Advisory Committee Satisfaction Survey

Status: Original and derived artifacts are available for this document.

Download: pdf

CDRH Advisory Committee Meeting Satisfaction Survey 2024
Introduction
OMB Control No.: 0910-0360
Expiration Date: 10/31/2026

Thank you for attending the Advisory Committee Meeting. The FDA’s Center for
Devices and Radiological Health (CDRH) would appreciate you completing this brief
survey. Your feedback will help CDRH improve future meetings.
Your participation / nonparticipation is completely voluntary, and your responses will not affect your
eligibility to receive any FDA services. In instances where respondent identity is needed (e.g., for followup of non-respondents), this information collection fully complies with all aspects of the Privacy Act and
data will be kept private to the fullest extent allowed by law.

Paperwork Reduction Act Statement: The Paperwork Reduction Act of 1995 provides that an agency may
not conduct or sponsor, and a person is not required to respond to a collection of information unless it
displays a valid OMB control number. The valid OMB control number for this information collection is
0910-0360. The time required to complete this information collection is estimated to average 5 minutes
per response. Send comments regarding this burden estimate or any other aspects of this collection of
information, including suggestions for reducing burden to PRAStaff@fda.hhs.gov.

CDRH Advisory Committee Meeting Satisfaction Survey 2024

* 1. On what date did you attend a CDRH Advisory Committee Meeting?

Meeting Date

Date

MM/DD/YYYY

* 2. Did you attend this Advisory Committee Meeting in person or virtually (online)?
In person
Virtually (online)

* 3. How satisfied or dissatisfied are you with the following aspects of the Advisory
Committee Meeting?
Strongly
Disagree

Disagree

Neutral

Agree

Strongly
Agree

N/A

Overall quality of the meeting
Audiovisual platform(s) used for the
meeting
Clarity of the FDA’s presentation
Format used for the panelists’ discussion
Your ability to communicate with the panel
Voting process

* 4. Was the start time of the Advisory Committee Meeting too early, too late, or just about
right?
Too early
Too late
Just about right

* 5. Was the Advisory Committee Meeting too short, too long, or just about right?
Too short
Too long
Just about right

6. What recommendations do you have for improving for future Advisory Committee
Meetings?

* 7. Which of the following best describes your role in attending the Advisory Committee
Meeting?
Patient/ Consumer/ Caregiver
Health Care Provider/ Health Professional Organization
Industry/ Industry Consultants/ Industry Trade Associations
Academia
Food and Drug Administration (FDA)
Other Federal Agency
Non-U.S. Regulator